Member Login
  1. Stocks
    2. /
  2. ConvaTec Group Plc (LSE: CTEC)
    3. /

LSE:CTEC (ConvaTec Group Plc)

About CTEC

ConvaTec Group Plc operates as holding company, which engages in medical business. Its activities include development, manufacture and sales of medical products and technologies related to therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care and management, continence and critical care, and infusion devices used in the treatment of diabetes and other conditions. The company was incorporated in 1978 and is headquartered in Reading, the United Kingdom.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

  • Should you invest £1,000 in Stv Group Plc right now?

    When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

    Mark and his analyst team just revealed what they believe are the 6 best stocks for investors to buy right now... and Stv Group Plc wasn’t on the list. Right now, they think there are 6 stocks that are better buys!

    See the 6 stocks

    • ConvaTec Group Plc (LSE: CTEC) Latest News

    Investing Articles

    Are FTSE 100 stocks ConvaTec Group plc & Merlin Entertainments plc bargain buys near 52-week lows?

    | Ian Pierce

    After recent sales warnings should investors take a chance on ConvaTec Group plc (LON: CTEC) and Merlin Entertainments plc (LON:…

    Read more »

    Investing Articles

    2 FTSE 100 stocks I’d buy in November

    | G A Chester

    G A Chester discusses why he'd buy these two FTSE 100 (INDEXFTSE:UKX) stocks.

    Read more »

    Investing Articles

    Why I’m not piling into this FTSE 100 turnaround stock just yet

    | Roland Head

    Roland Head takes a fresh look at a big faller from the FTSE 100 (INDEXFTSE:UKX).

    Read more »

    Investing Articles

    Why I’d buy this turnaround stock after today’s 20% share price fall

    | Peter Stephens

    This company appears to have turnaround potential despite releasing a disappointing update.

    Read more »

    Investing Articles

    2 top growth stocks I’d buy in August

    | Bilaal Mohamed

    Bilaal Mohamed reckons now could be a good time to buy these exciting growth stocks.

    Read more »

    Investing Articles

    2 promising growth stocks you probably haven’t considered

    | Jack Tang

    Should you consider these promising growth shares following their recent announcements?

    Read more »

    Investing Articles

    2 FTSE 100 growth stocks you can retire on

    | Rupert Hargreaves

    These two defensive growth champions could be great investments for retirement.

    Read more »

    Investing Articles

    Why I’d buy these 2 rising health stocks

    | G A Chester

    These two stocks appear to have long-term growth potential.

    Read more »

    Investing Articles

    These high-flying growth stocks could be hazardous to your wealth

    | Roland Head

    Roland Head explains why he's steering clear of these growth stocks.

    Read more »

    Hospital room
    Investing Articles

    Is Mediclinic International plc a screaming buy as shares surge 20% higher?

    | Ian Pierce

    Regulatory rollbacks send shares of Mediclinic International plc (LON: MDC) soaring 20%. Time to buy?

    Read more »

    Investing Articles

    The best 2 FTSE 100 stocks you may never have heard of

    | G A Chester

    Are these lower-profile blue chips set to outperform your FTSE 100 (INDEXFTSE:UKX) favourites?

    Read more »

    Investing Articles

    It isn’t too late to buy these FTSE 100 rockets

    | Harvey Jones

    These two FTSE 100 (INDEXFTSE: UKX) stars still have plenty of fuel in the tank, says Harvey Jones.

    Read more »